» Articles » PMID: 7853476

Mokola Virus Glycoprotein and Chimeric Proteins Can Replace Rabies Virus Glycoprotein in the Rescue of Infectious Defective Rabies Virus Particles

Overview
Journal J Virol
Date 1995 Mar 1
PMID 7853476
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

A reverse genetics approach which allows the generation of infectious defective rabies virus (RV) particles entirely from plasmid-encoded genomes and proteins (K.-K. Conzelmann and M. Schnell, J. Virol. 68:713-719, 1994) was used to investigate the ability of a heterologous lyssavirus glycoprotein (G) and chimeric G constructs to function in the formation of infectious RV-like particles. Virions containing a chloramphenicol acetyltransferase (CAT) reporter gene (SDI-CAT) were generated in cells simultaneously expressing the genomic RNA analog, the RV N, P, M, and L proteins, and engineered G constructs from transfected plasmids. The infectivity of particles was determined by a CAT assay after passage to helper virus-infected cells. The heterologous G protein from Eth-16 virus (Mokola virus, lyssavirus serotype 3) as well as a construct in which the ectodomain of RV G was fused to the cytoplasmic and transmembrane domains of the Eth-16 virus G rescued infectious SDI-CAT particles. In contrast, a chimeric protein composed of the amino-terminal half of the Eth-16 virus G and the carboxy-terminal half of RV G failed to produce infectious particles. Site-directed mutagenesis was used to convert the antigenic site III of RV G to the corresponding sequence of Eth-16 G. This chimeric protein rescued infectious SDI-CAT particles as efficiently as RV G. Virions containing the chimeric protein were specifically neutralized by an anti-Eth-16 virus serum and escaped neutralization by a monoclonal antibody directed against RV antigenic site III. The results show that entire structural domains as well as short surface epitopes of lyssavirus G proteins may be exchanged without affecting the structure required to mediate infection of cells.

Citing Articles

Rabies virus as vector for development of vaccine: pros and cons.

Li Y, Zhou H, Li Q, Duan X, Liu F Front Vet Sci. 2024; 11:1475431.

PMID: 39386254 PMC: 11461460. DOI: 10.3389/fvets.2024.1475431.


Glycoproteins of Predicted Amphibian and Reptile Lyssaviruses Can Mediate Infection of Mammalian and Reptile Cells.

Oberhuber M, Schopf A, Hennrich A, Santos-Mandujano R, Huhn A, Seitz S Viruses. 2021; 13(9).

PMID: 34578307 PMC: 8473393. DOI: 10.3390/v13091726.


Rhabdoviruses as vectors for vaccines and therapeutics.

Scher G, Schnell M Curr Opin Virol. 2020; 44:169-182.

PMID: 33130500 PMC: 8331071. DOI: 10.1016/j.coviro.2020.09.003.


Lyssavirus Vaccine with a Chimeric Glycoprotein Protects across Phylogroups.

Fisher C, Lowe D, Smith T, Yang Y, Hutson C, Wirblich C Cell Rep. 2020; 32(3):107920.

PMID: 32697993 PMC: 7373069. DOI: 10.1016/j.celrep.2020.107920.


Identification and Characterization of a Small-Molecule Rabies Virus Entry Inhibitor.

Du Pont V, Wirblich C, Yoon J, Cox R, Schnell M, Plemper R J Virol. 2020; 94(13).

PMID: 32321812 PMC: 7307179. DOI: 10.1128/JVI.00321-20.


References
1.
WIKTOR T, Gyorgy E, Schlumberger D, Sokol F, KOPROWSKI H . Antigenic properties of rabies virus components. J Immunol. 1973; 110(1):269-76. View

2.
Mebatsion T, Cox J, Conzelmann K . Molecular analysis of rabies-related viruses from Ethiopia. Onderstepoort J Vet Res. 1993; 60(4):289-94. View

3.
Kessler S . Use of protein A-bearing staphylococci for the immunoprecipitation and isolation of antigens from cells. Methods Enzymol. 1981; 73(Pt B):442-59. DOI: 10.1016/0076-6879(81)73084-2. View

4.
Anilionis A, Wunner W, Curtis P . Structure of the glycoprotein gene in rabies virus. Nature. 1981; 294(5838):275-8. DOI: 10.1038/294275a0. View

5.
Gorman C, Moffat L, Howard B . Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol. 1982; 2(9):1044-51. PMC: 369897. DOI: 10.1128/mcb.2.9.1044-1051.1982. View